Whalesbook
**
Energy Shock Spurs Pharma Price Hike Warning
The Indian pharmaceutical sector faces potential price increases, with Mankind Pharma Ltd. predicting that rising energy costs, driven by Middle East tensions, mean medicine prices will likely increase within the next month. Chief Operating Officer Arjun Juneja stated that while the industry has managed to operate on existing inventories, the impact of supply disruptions and soaring energy prices is now unavoidable. Manufacturing depends heavily on liquefied petroleum gas (LPG) and other petroleum-derived products for Active Pharmaceutical Ingredients (APIs) and drug formulations. With global crude oil prices jumping from approximately $70 per barrel to as high as $120 following the escalation of the Iran conflict, these higher input costs will directly increase consumer prices.
Reliance on Petrochemicals Fuels Vulnerability
The pharmaceutical industry's heavy reliance on crude oil and its derivatives is worsening the situation. Many essential medicines use petrochemicals like benzene, toluene, ethylene, and propylene, which are the base for APIs. Medical plastics used in syringes, IV bags, and packaging are also petrochemical derivatives, making their costs rise with oil prices. This link means supply chain disruptions, particularly those affecting transit routes like the Strait of Hormuz, directly threaten affordable production of critical healthcare products. India's need to import nearly 90% of its crude oil increases this vulnerability.
Wider Economic Impact and Industry Competition
The potential price hikes reflect broader economic challenges for India. Geopolitical turmoil has shaken the economy, with analysts warning of potential stagflation (rising inflation and slow growth) and a projected slowdown in GDP growth. A widening current account deficit and a weaker rupee add to the problems. Within the pharmaceutical sector, major players like Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Cipla Ltd. may see varied resilience. Companies with flexible supply chains or better hedging could fare better than those heavily reliant on volatile petrochemicals. Logistics costs have reportedly doubled, further increasing costs for domestic and export markets.
Margin Pressure and Structural Weaknesses Emerge
Beyond immediate price increases, margin pressure is a growing threat. Raw material costs, which some estimate have risen 20-50%, combined with higher shipping expenses, press down on drug makers' profits. Mankind Pharma's net debt of ₹7,746 crore as of September 2025 could grow larger with higher input costs. While the government reduced customs duties on certain petrochemical products until June 30, 2026, to ease some pressure, this is a temporary fix, not a long-term solution. The industry's reliance on imported energy and chemicals reveals a structural weakness. The government could also cap drug price increases, a potential barrier, especially if inflation worries consumers. Companies without strong cost control or varied sourcing will be at a disadvantage.
Outlook: Stabilization May Take Time
Arjun Juneja cautioned that a quick return to normal is unlikely. Supply chains may take six months to a year to stabilize, depending on geopolitical events and energy market shifts. This sustained uncertainty means the sector must manage higher costs and fragile supply chains for a long time. Although the industry is projected for significant long-term growth, reaching $130 billion by 2030, the near future involves balancing cost pressures with ensuring access to essential medicines.